捕捉12种选定罕见中枢神经系统肿瘤定义的演变:来自CBTRUS和NCI-CONNECT的及时报告
该研究利用CBTRUS数据库(含CDC NPCR与NCI SEER数据)计算2008-2019年12种罕见中枢神经系统肿瘤的年龄调整发病率、2004-2019年发病趋势及相对生存率,并估算2019年12月31日时点患病率。结果显示合计AAAIR为1.47/10万,室管膜瘤发病率最高(AAAIR=0.41/10万)且患病数最多(19,320例),室管膜瘤5年生存率最高(90.6%),原发性中枢神经系统肉瘤最低(7.7%)。
要点
- 12种罕见中枢神经系统肿瘤合计AAAIR为1.47/10万。
- 室管膜瘤AAAIR最高(0.41/10万),患病数最多(19,320例)。
- 室管膜瘤5年生存率最高(90.6%),原发性中枢神经系统肉瘤最低(7.7%)。
核心结论
- 这些数据为衡量临床照护影响、评估新疗法及罕见中枢神经系统肿瘤不断演变的组织病理学定义提供了手段。
研究设计与样本
- 使用CBTRUS数据库(CDC NPCR与NCI SEER合并数据集)计算2008-2019年诊断年份12种罕见中枢神经系统肿瘤的总体及按性别、种族-民族、年龄分层的平均年度年龄调整发病率(AAAIR)。
- 计算2004-2019年诊断年份的发病时间趋势。
- 使用NPCR数据计算相对生存率,并利用年度年龄别发病率和生存率估算2019年12月31日的时点患病率。
主要发现
- 12种肿瘤合计AAAIR为1.47/10万。
- 室管膜瘤发病率最高(AAAIR=0.41/10万)。
- 多数肿瘤类型在男性、成人(40岁及以上)或儿童(15岁以下)以及非西班牙裔白人中更常见。
- 室管膜瘤患病数最多(19,320例),其次为少突胶质细胞瘤(14,900例)。
- 室管膜瘤5年生存率最高(90.6%),原发性中枢神经系统肉瘤最低(7.7%)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Incidence, prevalence, and survival are population-based statistics describing cancer burden. The National Cancer Institute's (NCI) Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) specializes in tumor biology and outcomes for 12 rare CNS tumor types selected for their importance in adults, research interest, or potential for targeted treatment. The aim of this study was to update incidence, prevalence, and survival statistics for these tumors. METHODS: The Central Brain Tumor Registry of the United States (CBTRUS) database, a combined dataset of Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries (NPCR) and NCI's Surveillance, Epidemiology and End Results (SEER) data, was used to calculate average annual age-adjusted incidence rates (AAAIR) per 100,000 population overall and by sex, race-ethnicity, and age for diagnosis years 2008-2019. Incidence time trends were calculated for diagnosis years 2004-2019. NPCR data were used to calculate relative survival rates. Point prevalence on December 31, 2019 was estimated using annual age-specific incidence and survival. RESULTS: AAAIR was 1.47 per 100,000 for these tumors combined, with highest incidence in ependymomas (AAAIR = 0.41/100,000). Most tumor types were more common in males, adults (ages 40 + years) or children (ages < 15 years), and non-Hispanic White individuals. Ependymomas were the most prevalent tumor type (19,320 cases) followed by oligodendrogliomas (14,900 cases). Ependymomas had the highest five-year survival (90.6%) and primary CNS sarcomas the lowest (7.7%). CONCLUSIONS: These data provide means to measure the impact of clinical care and evaluate new therapies and the evolving histopathology definitions in rare CNS tumor types.
引用
- Price M, Neff C, Kruchko C, et al. Capturing evolving definitions of 12 select rare CNS tumors: a timely report from CBTRUS and NCI-CONNECT. J Neurooncol. 2023. PMID: 37980692. doi:10.1007/s11060-023-04480-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。